

## Short Communication



## DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

Giulia Bon<sup>a</sup>, Eriseld Krasniqi<sup>b</sup>, Manuela Porru<sup>c</sup>, Lorenzo D'Ambrosio<sup>d</sup>, Stefano Scalera<sup>e,f</sup>, Marcello Maugeri-Saccà<sup>g,h</sup>, Francesca Sofia Di Lisa<sup>b</sup>, Lorena Filomeno<sup>b</sup>, Teresa Arcuri<sup>b,i</sup>, Andrea Botticelli<sup>i</sup>, Daniele Santini<sup>i</sup>, Maria Agnese Fabbri<sup>j</sup>, Giuliana D'Auria<sup>k</sup>, Claudio Pulito<sup>l</sup>, Giovanni Blandino<sup>l</sup>, Caterina Marchiò<sup>m,n</sup>, Maddalena Barba<sup>h,\*</sup>, Gennaro Ciliberto<sup>o</sup>, Patrizia Vici<sup>b,1</sup>, Laura Pizzuti<sup>h,1</sup>

<sup>a</sup> Department of Research, Cellular Network and Molecular Therapeutic Target Unit, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy

<sup>b</sup> Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

<sup>c</sup> Department of Research, Diagnosis and Innovative Technologies, Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

<sup>d</sup> Department of Research, Diagnosis and Innovative Technologies, Tumor Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

<sup>e</sup> SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

<sup>f</sup> Department of Biology, PhD Program in Cellular and Molecular Biology, University of Rome "Tor Vergata", Rome, Italy

<sup>g</sup> Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

<sup>h</sup> Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, Rome 00144, Italy

<sup>i</sup> Department of Radiological, Oncological and Anatomic-Pathological Sciences, Medical Oncology A, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy

<sup>j</sup> Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy

<sup>k</sup> Medical Oncology, Sandro Pertini Hospital, Rome, Italy

<sup>l</sup> Oncogenomic and Epigenetic Unit, IRCCS, Regina Elena National Cancer Institute, Rome, Italy

<sup>m</sup> Department of Medical Sciences, University of Turin, Turin, Italy

<sup>n</sup> Pathology Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

<sup>o</sup> Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy

## ARTICLE INFO

## Keywords:

HER2 positive metastatic breast cancer  
Pertuzumab pretreated  
Real-world evidence  
PPP1R1B  
DARPP-32 and t-DARPP

## ABSTRACT

The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an advantage in terms of efficacy, for the newly available agents we lack effectiveness and tolerability evidence from the real-world setting. Similarly, the identification of predictive biomarkers might improve clinical decision. We herein describe the outline of a prospective/retrospective study which aims to explore the optimal sequence of treatment in HER2+, pertuzumab pre-treated ABC patients treated in II line with anti-HER2 agents in clinical practice. As part of the pre-clinical tasks envisioned by the STEP study, *in vitro* cell models of resistance were exploited to investigate molecular features associated with reduced efficacy of HER2 targeting agents at the transcript level. The aggressive behavior of resistant cell populations was measured by growth assessment in mouse models. This approach led to the identification of DARPP-32 and t-DARPP proteins as possible predictive biomarkers of efficacy of anti-HER2 agents. Biomarkers validation and the clinical goals will be reached through patients' inclusion into two independent cohorts, i.e., the prospective and retrospective cohorts, whose setup is currently ongoing.

Optimal Sequence of Treatment in HER2+ Pertuzumab-pretreated advanced breast cancer patients.

\* Corresponding author.

E-mail address: [maddalena.barba@ifo.it](mailto:maddalena.barba@ifo.it) (M. Barba).

<sup>1</sup> Equal contributors.

<https://doi.org/10.1016/j.neo.2023.100937>

Received 13 September 2023; Accepted 20 September 2023

Available online 26 September 2023

1476-5586/© 2023 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

The therapeutic landscape of HER2 positive (HER2+) advanced breast cancer (ABC) is dramatically evolving. The entrance of newly available anti-HER2 agents in clinical practice has significantly impacted patients' outcome, and now imposes an extensive reconsideration of the pre-existing scenarios. In addition, results from randomized trials are not fully generalizable to patients' populations from the real world setting [1,2].

In our prior work on the optimal sequence of treatment in HER2+ ABC patients, we exploited cell models of resistance. Cell populations resistant to trastuzumab+pertuzumab combination showed a marked reduction of HER2 expression on the cell membrane and its translocation to the nucleus, compared with trastuzumab-resistant and parental cells. This reduction resulted in lower efficacy of Trastuzumab emtansine (T-DM1), which may help interpret the significantly less favourable outcome of 2nd-Line-T-DM1 observed in 177 pertuzumab-pre-treated patients vs 194 pertuzumab-naïve patients [3].

HER2 downregulation may be part of an evolution process dictated by HER2 targeting agents. Adaptation may require multiple mechanisms including gene deregulations, fine tuning of signaling pathways activity, and/or changes in the interactions with tumor microenvironment [4,5]. Such phenotypic changes may include collateral sensitivities and/or overexpression of predictive biomarkers.

The STEP observational study is focused on the optimal sequence of treatment in HER2+, pertuzumab-pre-treated ABC pts. Both preclinical and clinical tasks are foreseen. We herein presented the outcome of the inherent preclinical research activities, which have led to the identification and characterization of DARPP-32 (dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000) and t-DARPP (truncated isoform of dopamine- and cAMP-regulated phosphoprotein) as potential predictors of efficacy of the anti-HER2 agents. We have also envisioned both a prospective (N=50) and a retrospective (N=50) patients' cohort. The predictive role of DARPP-32/t-DARPP will be further investigated in the retrospective cohort, while the prospective cohort will generate real word evidence on the effectiveness/tolerability of the most innovative anti-HER2 agents and investigate the predictive/prognostic role of circulating biomarkers.

## Materials and methods

The STEP study is as a multicentric, observational study. The IRCCS

Regina Elena Cancer Institute acts as coordinating center. The study protocol was approved by the Institutional Review Board of the coordinating and satellite centers (Register code: 1809/22). A flow diagram of the STEP is displayed in Fig. 1, while the methods applied to the clinical tasks are broadly summarized in the appendix 1.

## Cell lines

The BT474 HER2+ breast cancer (BC) cell populations resistant to trastuzumab (T), pertuzumab (P), and trastuzumab+pertuzumab combination (TP) were obtained as reported elsewhere [1]. The cultures were maintained in RPMI medium supplemented with 10 % FBS, 1 % penicillin/streptomycin and 1 % glutamine (Invitrogen, Milan, Italy), and periodically tested for mycoplasma contamination.

## Quantitative RT-PCR

Total RNA from parental and resistant cell lines was isolated by PureLink RNA Mini kit (Invitrogen) and reverse-transcribed using PrimeScript RT reagent kit (Takara), according to manufacturer's recommendations. Quantitative PCR (qPCR) was performed by SYBR Green on an ABI Prism 7500 apparatus (Applied Biosystems, Glasgow, UK) in 2 independent experiments in triplicate. The comparative threshold ( $\Delta\text{Ct}$ ) method was used. Specific primer sequences were:

Darpp-32 FW: 5'-AGAGACACACGCGGAGAGGA-3'  
 Darpp-32 REV: 5'-TCTGCCTCTCCCGTCCCTCT-3'  
 t-Darpp FW: 5'-CTGCAGCCTTACAGAGACTGG-3'  
 t-Darpp REV: 5'-TGAGGCTCAGGGACCCAAAG-3'  
 GAPDH FW: 5'-TCCCTGAGCTGAACGGGAAG-3'  
 GAPDH REV: 5'-GGAGGAGTGGGTGTCGCTGT-3'

## Antibodies and western blot analysis

Rabbit anti-DARPP32 (#2306) and mouse anti-HSP70 (N27F34) antibodies were purchased from Cell Signaling (Milan, IT) and Stressgen (Milan, IT), respectively. Peroxidase-conjugated secondary antibodies anti-IgGs were from Cappel and/or BioRad (Milan, IT).

To analyze t-DARPP and HSP70 proteins expression, the cells were lysed with RIPA buffer [50 mMTris (pH 8), 150 mMNaCl, 1 % Nonidet P40, 0.1 % deoxycholate, 0.1 % SDS, 1 mM PMSF, 5 mM Na<sub>3</sub>VO<sub>4</sub>, 50 mM protease inhibitors (SIGMA-Aldrich, Milan, IT)] for 30 min at 4°C. Total




Fig. 1. Flow diagram of the STEP observational trial.

cell lysates were clarified by centrifugation at 14,000 rpm for 30 min at 4 °C. Aliquots of cell extracts containing equivalent amount of proteins were treated at 95 °C for 5 min, resolved by SDS-polyacrylamide gel electrophoresis 4-15 % (SDS-PAGE), and transferred to nitrocellulose. The horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit were used as secondary antibodies. Signals were detected by Lumina-tMClassico Western HRP substrate (Millipore). Identical amounts of total protein from three independent experiments were pooled and analyzed. Total loaded proteins were normalized by anti-HSP70.

### RNA sequencing (RNA-seq) analysis

RNA-seq (whole-transcriptome sequencing) analysis was carried out in parental and resistant (T, TP) BT474 cell populations. A pertuzumab-resistant cell population (P) was also assessed as a further control population. Raw data processing from RNA-Seq experiments was performed by RNA-Seq Analysis Pipeline (RAP) webtool [6] using default parameters and hg19 as reference genome. Differentially expressed genes were identified with the *cuffdiff* module and genes with adjusted *P*-value <0.05 (Bonferroni correction) were considered significantly modulated between each condition. Plots were generated using the R statistical environment (v.4.2.3).

### In vivo xenograft experiments

All animal procedures were compliant with the national and


international directives (D.L. March 4th, 2014, no. 26; directive 2010/63/EU of the European Parliament and of the council; Guide for the Care and Use of Laboratory Animals, United States National Research Council 2011; Animal Research Guidelines Reporting of *In Vivo* Experiments (ARRIVE) guidelines and approved by the Italian Ministry of Health; authorization n. 743/2020-PR, released on July 28th 2020). The mice were maintained in high-efficiency, particulate air HEPA-filtered racks and were fed autoclaved laboratory rodent diet.

CB17-SCID (CB17/1cr-Prkdcscid/IcrIcoCrI, 6 week old) female mice (Charles River Laboratories, Calco, Italy) were injected subcutaneously with  $5 \times 10^6$  of parental and resistant (T, TP) BT474 cells. Animals were supplemented with 200nM 17 $\beta$ -estradiol (E4389, Sigma-Aldrich) in drinking water.

Tumor volumes were measured in two dimensions using a caliper and calculated by the formula  $a \times b^2 / 2$ , where “a” and “b” are the long and short sizes of the tumor, respectively. Each experimental group included six mice.

## Results

Mechanisms of resistance to HER2-targeted agents were explored in cell models of resistance to T, P, and their combination (TP) previously derived from BT474 and SkBr3 HER2+ BC cell lines and characterized *in vitro* [3]. We assessed the *in vivo* growth of BT474-derived T and TP cell populations following subcutaneous injection in immunocompromised mice. Unlike parental BT474-derived xenografts, T and TP-derived ones



**Fig. 2.** Pre-clinical models of resistance to anti-HER2 agents. **A.** Growth of tumors derived from subcutaneous implantation of CTR, T, and TP BT474 cells. **B.** RNA-Seq heatmap of the 1000 genes differentially expressed in TP as compared to T resistant cells (FC>1), showed in CTR, T, P, and TP cell populations (SkBr3 and BT474). **C.** Schematic representation of human PPP1R1B gene and exon organization of DARPP32 and its truncated isoform t-DARPP. **D.** Distribution of HER2 positivity among PPP1R1B amplified and wild type breast cancer cases from Metabric series. **E.** mRNA levels of t-DARPP and DARPP-32 in resistant BT474 and SkBr3 cells, represented as Fold Change as compared to parental cell population. **F.** Western Blot analysis revealing t-DARPP expression in resistant and parental BT474 and SkBr3 cell populations. The results are presented as mean +/- standard deviation of three independent experiments (\**p* < 0.05; \*\**p* < 0.001; \*\*\**p* < 0.0001).

did not require estrogens supplementation for their growth (data available upon request). When compared with T and parental xenografts, the TP ones showed a significantly higher growth rate (Fig. 2A).

To identify candidate molecular predictors of cross-resistance among sequential HER2-targeting agents, we used RNAseq to profile resistant and parental BT474 and SkBr3 cell populations. The *PPP1R1B* gene ranked as the top differentially expressed gene in BT474 cells resistant to dual HER2 blockade and was associated with resistance to trastuzumab in SkBr3 (Fig. 2B).

The *PPP1R1B* gene encodes for DARPP-32 and its truncated isoform (t-DARPP). In this latter form, this protein lacks the first 36 amino acids at the N-terminus (Fig. 2C). Since *PPP1R1B* is located together with *ERBB2* on the 17q12-q21 amplicon, co-amplification of these two genes is a likely event. Data from the of the Metabric dataset of BCs (N=2,509) found a *ERBB2* gene amplification in about 80 % of the cases with *PPP1R1B* gene amplification, which *per se* shows an overall 13 % frequency (Fig. 2D).

To validate the RNAseq results, we first measured the levels of t-DARPP and DARPP-32 mRNAs by RT-PCR in cell models. We found a marked induction of both t-DARPP (up to 280-fold) and DARPP-32 (up to 40-fold) in BT474 TP cells (Fig. 2E, leftmost upper panel). Both isoforms were upregulated in SkBr3 T cells (t-DARPP 37-fold, and DARPP-32 27-fold induction) compared with parental SkBr3 (Fig. 2E, rightmost upper panel). The t-DARPP protein was significantly overexpressed (Fig. 2E, lower panels). Although co-amplification of *PPP1R1B* and *ERBB2* was a recurrent event in HER2+ BC, we observed different patterns in our models. Increased mRNA levels of DARPP isoforms were accompanied by reduced HER2 expression [3], suggesting that a transcription-level regulatory mechanism may be involved in the onset of resistance to HER2 targeting agents.

## Discussion

In pre- and post-therapy tissue sections from two HER2+ ABC patients treated with TP combination, we observed that the mRNA levels of both DARPP-32 and t-DARPP underwent significant but opposite alterations. Although extremely preliminary, this observation may support the predictive potential of these two DARPP isoforms. To our knowledge, only one single study has reported on the predictive role of DARPP-32 expression in ABC patients treated with trastuzumab [7]. Although t-DARPP expression has been involved in resistance to trastuzumab in *in vitro* cell models [8–10], we lack data on patients' outcomes. The analysis of biological samples from the STEP retrospective cohort will add to this topic. Thus far, the retrospective cohort includes 30 patients, while 9 patients have entered the prospective cohort out of 16 patients screened.

## Conclusions

The impact of innovative anti-HER2 agents on the general patients' population will change its characteristics, along with the outcome of the lines of treatment administered sequentially in the near future. As a consequence, treatment sequence must be reconsidered. The STEP study holds the potentials to integrate current evidence by adding high quality RWE to the current scenario and to unveil key biological mechanisms of resistance to the currently available anti-HER2 agents.

## Funding

This research was supported by Funds Ricerca Corrente 2023 from Italian Ministry of Health and GR-2018-12367431/Italian Minister of Health.

## CRedit authorship contribution statement

**Giulia Bon:** Data curation, Formal analysis, Methodology,

Investigation, Writing – original draft. **Eriseld Krasniqi:** Writing – review & editing. **Manuela Porru:** Writing – review & editing. **Lorenzo D'Ambrosio:** Writing – review & editing. **Stefano Scalera:** Writing – review & editing. **Marcello Maugeri-Saccà:** Writing – review & editing. **Francesca Sofia Di Lisa:** Writing – review & editing. **Lorena Filomeno:** Writing – review & editing. **Teresa Arcuri:** Writing – review & editing. **Andrea Botticelli:** Writing – review & editing. **Daniele Santini:** Writing – review & editing. **Maria Agnese Fabbri:** Writing – review & editing. **Giuliana D'Auria:** Writing – review & editing. **Claudio Pulito:** Data curation, Investigation, Writing – review & editing. **Giovanni Blandino:** Supervision, Writing – review & editing. **Caterina Marchiò:** Writing – review & editing. **Maddalena Barba:** Investigation, Writing – original draft. **Gennaro Ciliberto:** Writing – review & editing. **Patrizia Vici:** Supervision, Writing – review & editing. **Laura Pizzuti:** Conceptualization, Methodology, Data curation, Investigation, Writing – original draft, Project administration, Funding acquisition.

## Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FSDL: Ipsen and Novartis, outside the submitted work. AB: Pfizer, Roche, Lilly, Novartis, Msd, Seagen, Gilead and Daiichi Sankyo, outside the submitted work. DS: Amgen, Astellas, Astrazeneca, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, outside the submitted work. GDA: Novartis, Amgen, Eli Lilly, outside the submitted work. CM: Bayer, Roche, AstraZeneca and Daiichi-Sankyo, outside the submitted work. P.V.: Pfizer, Novartis, Eisai, Daiichi Sankyo and Eli Lilly, outside of the manuscript under consideration. L.P.: Novartis and Pfizer, outside of the manuscript under consideration. No potential conflicts of interest were disclosed for other authors

## Acknowledgments

We thank Consorzio Interuniversitario Nazionale per la Bio-Oncologia for administrative and technical support and Dr Federico Cappuzzo for making available personnel from his division.

## Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.neo.2023.100937](https://doi.org/10.1016/j.neo.2023.100937).

## References

- [1] S.M. Swain, S.B. Kim, J. Cortés, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. M. Ferrero, A. Schneeweiss, A. Knott, et al., Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a multicenter, double-blind, placebo-controlled, phase 3 study, *Lancet Oncol.* 14 (2013) 461–471, [https://doi.org/10.1016/S1470-2045\(13\)70130-X](https://doi.org/10.1016/S1470-2045(13)70130-X).
- [2] G. Nader-Marta, D. Martins-Branco, E. de Azambuja, How we treat patients with metastatic HER2-positive breast cancer, *ESMO Open* 7 (2022), 100343, <https://doi.org/10.1016/j.esmoop.2021.100343>.
- [3] G. Bon, L. Pizzuti, V. Laquintana, R. Loria, M. Porru, C. Marchiò, E. Krasniqi, M. Barba, M. Maugeri-Saccà, T. Gamucci, et al., Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study, *J. Clin. Exp. Cancer Res.* 39 (2020) 279, <https://doi.org/10.1186/s13046-020-01797-3>.
- [4] A. Mullard, Stemming the tide of drug resistance in cancer, *Nat. Rev. Drug Discov.* 19 (2020) 221–223, <https://doi.org/10.1038/d41573-020-00050-y>.
- [5] S.W. Brady, J.A. McQuerry, Y. Qiao, S.R. Piccolo, G. Shrestha, D.F. Jenkins, R. M. Layer, B.S. Pedersen, R.H. Miller, A. Esch, et al., Combating subclonal evolution of resistant cancer phenotypes, *Nat. Commun.* 8 (2017) 1231, <https://doi.org/10.1038/s41467-017-01174-3>.
- [6] M. D'Antonio, P. D'Onorio De Meo, M. Pallocca, A.M. D'Erchia, R.A. Calogger, T. Castrignanò, G. Pesole, RAP: RNA-Seq Analysis Pipeline, a new cloud-based NGS web application, *BMC Genom.* 16 (2015) S3, <https://doi.org/10.1186/1471-2164-16-S6-S3>.
- [7] S. Kotecha, M.N. Lebot, B. Sukkarn, G. Ball, P.M. Moseley, S.Y. Chan, A.R. Green, E. Rakha, I.O. Ellis, S.G. Martin, et al., Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective

- analysis of protein and mRNA expression, *Sci. Rep.* 9 (2019) 16987, <https://doi.org/10.1038/s41598-019-53529-z>.
- [8] A. Belkhiri, A.A. Dar, D.F. Peng, M.H. Razvi, C. Rinehart, C.L. Arteaga, W. El-Rifai, Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells, *Clin. Cancer Res.* 14 (2008) 4564–4571, <https://doi.org/10.1158/1078-0432.CCR-08-0121>.
- [9] G. Lenz, A. Hamilton, S. Geng, T. Hong, M. Kalkum, J. Momand, S.E. Kane, J. M. Huss, t-darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells, *Clin. Cancer Res.* 24 (2018) 1216–1226, <https://doi.org/10.1158/1078-0432.CCR-17-0824>.
- [10] J. Hong, A. Katsha, P. Lu, Y. Shyr, A. Belkhiri, W. El-Rifai, Regulation of ERBB2 receptor by t-Darpp mediates trastuzumab resistance in human esophageal adenocarcinoma, *Cancer Res.* 72 (2012) 4504–4514, <https://doi.org/10.1158/0008-5472.CAN-12-1119>.